Mycophenolate Mofetil, Prednisone, Tacrolimus, and Thymoglobulin Combination Therapy

Based on the search results, I can provide information about the combination therapy of mycophenolate mofetil, prednisone, tacrolimus, and Thymoglobulin.\n\nThis is a combination immunosuppressive regimen commonly used in organ transplantation, particularly for preventing rejection in solid organ transplants. The search results show this combination has been studied and used in various transplant settings, including solitary pancreas transplantation, kidney transplantation, and other solid organ transplants[1][4].\n\n## Components of the Combination\n\n**Mycophenolate Mofetil (CellCept®)**\n- An immunosuppressant that inhibits lymphocyte proliferation\n- Taken orally every 12 hours, either with or without food (as long as it's done consistently)[4]\n- Often used in combination with other anti-rejection medications\n\n**Prednisone (Novo Prednisone®, Apo Prednisone®)**\n- A corticosteroid that suppresses immune system activity\n- Typically tapered to a maintenance dose (e.g., 20 mg once daily as mentioned in one protocol)[1]\n- Part of standard immunosuppressive regimens\n\n**Tacrolimus (Prograf® or Advagraf®)**\n- A calcineurin inhibitor that prevents T-cell activation\n- Available in regular release (Prograf®, taken every 12 hours) or extended release (Advagraf®, taken once daily) formulations[4]\n- Blood levels are monitored to ensure appropriate dosing\n- Common side effects include headache, tremors, elevated potassium, high blood pressure, decreased kidney function, and elevated blood sugar levels[4]\n\n**Thymoglobulin (Antilymphocyte Globulin)**\n- A polyclonal rabbit-derived antilymphocyte antibody\n- Used as induction therapy, typically administered in the immediate post-transplant period\n- Dosing is often adjusted based on white blood cell and lymphocyte counts[1]\n- In one study, patients received 3-7 doses over the first seven post-operative days at a dose of 0.85 ± 0.27 mg/kg/day[1]\n\n## Clinical Use and Outcomes\n\nThis combination therapy has shown excellent outcomes in transplant patients. In a study of solitary pancreas transplantation using reduced-dose Thymoglobulin induction with lower-dose tacrolimus and mycophenolate mofetil, the one-year patient and graft survival rates were 100% and 96%, respectively, with an acute rejection rate of 27.3%[1].\n\nThe combination is designed to provide comprehensive immunosuppression while minimizing the side effects of individual agents. Monitoring of drug levels, particularly for tacrolimus, is important to ensure adequate immunosuppression while minimizing toxicity[4].\n\nDifferent transplant centers may adjust the specific dosing of these medications based on patient characteristics, type of transplant, and institutional protocols. For example, in the study mentioned, Thymoglobulin dosing was reduced by 43% compared to standard recommendations by monitoring white blood cell and lymphocyte counts, while still achieving excellent outcomes[1].

Brand names

Novo PrednisoneApo Prednisone